HNST enters its Q1 2026 results — due after the bell tomorrow, May 7 — with short sellers in full retreat and the stock up 22% in a month, a notably charged setup for a sub-$4 name in personal care.
The most compelling angle right now is positioning. Short interest has fallen sharply from a peak of roughly 12.3 million shares in early April to just over 10.4 million, a decline of about 15% in five weeks. That now translates to 9.3% of the free float — still meaningful, but trending down hard. The borrow market reinforces that picture: cost to borrow is a negligible 0.59% APR, and availability is wide open, meaning there is no squeeze pressure in the lending pool. The ORTEX short score of 61 has also eased from highs above 63 earlier in April, tracking the retreat in positioned short interest.
Options traders are not sounding any alarm. The put/call ratio is running at 0.11 — practically its floor — and barely a standard deviation above the already-low 20-day mean of 0.105. The 52-week high on that ratio is 0.39, which gives a sense of how little downside protection is being bought. That combination of retreating shorts and call-heavy options makes the current setup look more like lean-on-strength positioning than cautious hedging ahead of a catalyst.
The Street is in an awkward spot. The consensus rating sits at Buy, with four analysts on that side, but the most recent coverage — all from February 26 — saw Telsey Advisory maintain Market Perform at $3.00 and Freedom Broker trim its target modestly from $3.20 to $3.00. JPMorgan's downgrade to Underweight in mid-January is the most bearish recent action from a bellwether firm, and the mean price target of $3.50 is barely above the current price of $3.45. Analyst data here is stale (last updated late February), so the full picture heading into tomorrow's print is incomplete. On valuation, the P/E has expanded 20% over the past 30 days to 28.5x — a notable re-rating for a name that doesn't yet reliably generate earnings. The bull case rests on digital growth, category expansion, and improving margins. Bears point to continued pressure in diapers and apparel, negative margins at the group level, and the risk that cost-cutting alone can't offset weak demand.
The factor score picture is genuinely interesting. EPS momentum ranks in the 98th percentile over 90 days — the company has been consistently beating already-improving consensus estimates. That sits in sharp contrast to an EPS surprise rank of just 3, suggesting the beats have been against inflated, recently-revised numbers rather than conservative bars. That tension will be tested tomorrow.
The last two earnings prints produced wildly divergent reactions: a 23% single-day gain in February after Q4 results, followed (earlier in the records) by a 6% drop. The five-day follow-through after the strong February print was 30%. Institutional ownership adds context: Vanguard added over a million shares in Q1, while Portolan Capital — a known small-cap active manager — cut its position by more than 2 million shares in Q4 2025. That split between passive accumulation and active trimming reflects exactly the bull-bear divide playing out in the analyst community.
What to watch tomorrow: whether the Q1 print confirms the EPS momentum story or reveals that the upgrade cycle has already been priced into the stock's 22% one-month rally.
See the live data behind this article on ORTEX.
Open HNST on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
